• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多维机器学习和分子动力学模拟对NBTI抗菌剂针对DNA旋转酶的动态分析和结合亲和力预测

Dynamic Profiling and Binding Affinity Prediction of NBTI Antibacterials against DNA Gyrase Enzyme by Multidimensional Machine Learning and Molecular Dynamics Simulations.

作者信息

Kokot Maja, Minovski Nikola

机构信息

Laboratory for Cheminformatics, Theory Department, National Institute of Chemistry, Hajdrihova 19, 1001 Ljubljana, Slovenia.

The Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.

出版信息

ACS Omega. 2024 Apr 11;9(16):18278-18295. doi: 10.1021/acsomega.4c00036. eCollection 2024 Apr 23.

DOI:10.1021/acsomega.4c00036
PMID:38680300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11044241/
Abstract

Bacterial type II topoisomerases are well-characterized and clinically important targets for antibacterial chemotherapy. Novel bacterial topoisomerase inhibitors (NBTIs) are a newly disclosed class of antibacterials. Prediction of their binding affinity to these enzymes would be beneficial for design/optimization of new NBTIs. Utilizing NBTI experimental data, we constructed two comprehensive multidimensional DNA gyrase surrogate models for ( = 0.791) and ( = 0.806). Both models accurately predicted the ICs of 26 NBTIs from our recent studies. To investigate the NBTI's dynamic profile and binding to both targets, 10 selected NBTIs underwent molecular dynamics (MD) simulations. The analysis of MD production trajectories confirmed key hydrogen-bonding and hydrophobic contacts that NBTIs establish in both enzymes. Moreover, the binding free energies of selected NBTIs were computed by the linear interaction energy (LIE) method employing an in-house derived set of fitting parameters (α = 0.16, β = 0.029, γ = 0.0, and intercept = -1.72), which are successfully applicable to DNA gyrase of Gram-positive/Gram-negative pathogens. Both methods offer accurate predictions of the binding free energies of NBTIs against and DNA gyrase. We are confident that this integrated modeling approach could be valuable in the design and optimization of efficient NBTIs for combating resistant bacterial pathogens.

摘要

细菌II型拓扑异构酶是特征明确且在抗菌化疗中具有重要临床意义的靶点。新型细菌拓扑异构酶抑制剂(NBTIs)是一类新披露的抗菌药物。预测它们与这些酶的结合亲和力将有助于新型NBTIs的设计/优化。利用NBTI实验数据,我们构建了两个综合多维DNA促旋酶替代模型,其相关系数分别为( = 0.791)和( = 0.806)。两个模型都准确预测了我们近期研究中26种NBTIs的半数抑制浓度(ICs)。为了研究NBTI的动态特征及其与两个靶点的结合情况,对10种选定的NBTIs进行了分子动力学(MD)模拟。MD模拟生成轨迹的分析证实了NBTIs在两种酶中形成的关键氢键和疏水相互作用。此外,采用内部推导的一组拟合参数(α = 0.16,β = 0.029,γ = 0.0,截距 = -1.72),通过线性相互作用能(LIE)方法计算了选定NBTIs的结合自由能,这些参数成功应用于革兰氏阳性/革兰氏阴性病原体的DNA促旋酶。两种方法都能准确预测NBTIs对 和DNA促旋酶的结合自由能。我们相信,这种综合建模方法在设计和优化对抗耐药细菌病原体的高效NBTIs方面可能具有重要价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/35966e877086/ao4c00036_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/957626c51d98/ao4c00036_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/48744b005aa4/ao4c00036_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/3743d7f8c150/ao4c00036_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/17940a21b061/ao4c00036_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/e708253a4b38/ao4c00036_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/b1d688f5ab39/ao4c00036_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/42e139237d52/ao4c00036_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/5409dfe9862d/ao4c00036_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/33c74ce0326b/ao4c00036_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/35966e877086/ao4c00036_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/957626c51d98/ao4c00036_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/48744b005aa4/ao4c00036_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/3743d7f8c150/ao4c00036_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/17940a21b061/ao4c00036_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/e708253a4b38/ao4c00036_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/b1d688f5ab39/ao4c00036_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/42e139237d52/ao4c00036_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/5409dfe9862d/ao4c00036_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/33c74ce0326b/ao4c00036_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76e5/11044241/35966e877086/ao4c00036_0010.jpg

相似文献

1
Dynamic Profiling and Binding Affinity Prediction of NBTI Antibacterials against DNA Gyrase Enzyme by Multidimensional Machine Learning and Molecular Dynamics Simulations.通过多维机器学习和分子动力学模拟对NBTI抗菌剂针对DNA旋转酶的动态分析和结合亲和力预测
ACS Omega. 2024 Apr 11;9(16):18278-18295. doi: 10.1021/acsomega.4c00036. eCollection 2024 Apr 23.
2
Exploring Alternative Pathways to Target Bacterial Type II Topoisomerases Using NBTI Antibacterials: Beyond Halogen-Bonding Interactions.利用NBTI抗菌剂探索靶向细菌II型拓扑异构酶的替代途径:超越卤键相互作用
Antibiotics (Basel). 2023 May 18;12(5):930. doi: 10.3390/antibiotics12050930.
3
Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site.新型细菌拓扑异构酶抑制剂利用 Asp83 和 DNA 回旋酶结合位点的固有柔性。
Int J Mol Sci. 2018 Feb 3;19(2):453. doi: 10.3390/ijms19020453.
4
Diminishing hERG inhibitory activity of aminopiperidine-naphthyridine linked NBTI antibacterials by structural and physicochemical optimizations.通过结构和理化性质优化降低氨基哌啶-萘啶连接的 NBTI 类抗菌药物对 hERG 的抑制活性。
Bioorg Chem. 2022 Nov;128:106087. doi: 10.1016/j.bioorg.2022.106087. Epub 2022 Aug 11.
5
Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.基于萘啶酮/氨基哌啶的抗菌药物的双重作用模式,该药物靶向拓扑异构酶 II 和拓扑异构酶 IV。
Biochemistry. 2019 Nov 5;58(44):4447-4455. doi: 10.1021/acs.biochem.9b00805. Epub 2019 Oct 28.
6
Structure-based design of novel combinatorially generated NBTIs as potential DNA gyrase inhibitors against various Staphylococcus aureus mutant strains.基于结构的新型组合生成的NBTIs设计,作为针对各种金黄色葡萄球菌突变菌株的潜在DNA回旋酶抑制剂。
Mol Biosyst. 2017 Jun 27;13(7):1406-1420. doi: 10.1039/c7mb00168a.
7
Actions of a Novel Bacterial Topoisomerase Inhibitor against Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks.新型细菌拓扑异构酶抑制剂对拓扑异构酶 II 和拓扑异构酶 IV 的作用:增强双链 DNA 断裂。
Int J Mol Sci. 2023 Jul 28;24(15):12107. doi: 10.3390/ijms241512107.
8
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus.通过对金黄色葡萄球菌耐药突变体的表征深入了解新型细菌拓扑异构酶抑制剂的抑制机制。
Antimicrob Agents Chemother. 2015 Sep;59(9):5278-87. doi: 10.1128/AAC.00571-15. Epub 2015 Jun 15.
9
Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy.含酰胺的NBTI抗菌剂,其对hERG的抑制作用降低,对革兰氏阳性菌的抗菌活性得以保留,且具有体内疗效。
Eur J Med Chem. 2023 Mar 15;250:115160. doi: 10.1016/j.ejmech.2023.115160. Epub 2023 Feb 2.
10
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.苯并咪唑类:通过骨架变形得到的新型分枝杆菌gyrase抑制剂
ACS Med Chem Lett. 2014 Jun 2;5(7):820-5. doi: 10.1021/ml5001728. eCollection 2014 Jul 10.

本文引用的文献

1
Exploring Alternative Pathways to Target Bacterial Type II Topoisomerases Using NBTI Antibacterials: Beyond Halogen-Bonding Interactions.利用NBTI抗菌剂探索靶向细菌II型拓扑异构酶的替代途径:超越卤键相互作用
Antibiotics (Basel). 2023 May 18;12(5):930. doi: 10.3390/antibiotics12050930.
2
Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy.含酰胺的NBTI抗菌剂,其对hERG的抑制作用降低,对革兰氏阳性菌的抗菌活性得以保留,且具有体内疗效。
Eur J Med Chem. 2023 Mar 15;250:115160. doi: 10.1016/j.ejmech.2023.115160. Epub 2023 Feb 2.
3
Diminishing hERG inhibitory activity of aminopiperidine-naphthyridine linked NBTI antibacterials by structural and physicochemical optimizations.
通过结构和理化性质优化降低氨基哌啶-萘啶连接的 NBTI 类抗菌药物对 hERG 的抑制活性。
Bioorg Chem. 2022 Nov;128:106087. doi: 10.1016/j.bioorg.2022.106087. Epub 2022 Aug 11.
4
The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.新型细菌拓扑异构酶抑制剂的结构特征决定了它们对拓扑异构酶 IV 的活性。
J Med Chem. 2022 May 12;65(9):6431-6440. doi: 10.1021/acs.jmedchem.2c00039. Epub 2022 May 3.
5
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担:系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
6
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections.三期临床试验中治疗单纯性尿路感染时格帕沙星(GSK2140944)的剂量选择。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0149221. doi: 10.1128/AAC.01492-21. Epub 2022 Jan 3.
7
Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with Efficacy against MRSA.优化拓扑异构酶 IV 的效力、ADMET 性质和 hERG 抑制作用的 5-氨基-1,3-二恶烷连接的新型细菌拓扑异构酶抑制剂:鉴定一种对 MRSA 有效的先导化合物。
J Med Chem. 2021 Oct 28;64(20):15214-15249. doi: 10.1021/acs.jmedchem.1c01250. Epub 2021 Oct 6.
8
Structurally Optimized Potent Dual-Targeting NBTI Antibacterials with an Enhanced Bifurcated Halogen-Bonding Propensity.具有增强的分叉卤键倾向的结构优化的强效双靶点NBTI抗菌剂。
ACS Med Chem Lett. 2021 Aug 16;12(9):1478-1485. doi: 10.1021/acsmedchemlett.1c00345. eCollection 2021 Sep 9.
9
A Fine-Tuned Lipophilicity/Hydrophilicity Ratio Governs Antibacterial Potency and Selectivity of Bifurcated Halogen Bond-Forming NBTIs.精细调节的亲脂性/亲水性比率决定了分叉型卤素键形成的NBTIs的抗菌效力和选择性。
Antibiotics (Basel). 2021 Jul 15;10(7):862. doi: 10.3390/antibiotics10070862.
10
Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds.强效 DNA 拓扑异构酶抑制剂通过对称分叉的卤键不对称地结合其靶标。
Nat Commun. 2021 Jan 8;12(1):150. doi: 10.1038/s41467-020-20405-8.